B-ALL remodels the microenvironment around the leukemia to alter monocyte differentiation. Leukemia-associated monocyte abundance predicts pediatric and adult B-ALL patient survival and supports B-ALL progression and treatment evasion (Witkowski et al. Cancer Cell 2022)
Emerging therapies allow a B-ALL patient's own T cells to be trained to recognize and kill B-ALL blasts. The B-ALL blast cell surface is often littered with a protein known as CD19, which is detected and bound by B-ALL-seeking T cells to kill the leukemic cell target. However, blasts expressing low surface CD19 levels may fail to be found and destroyed.
Leukemia mouse models have proven to be an invaluable tool for exploring new treatment options for hematological malignancies, however, there are limited ALL mouse models that mimic the genetic and gene expression features of B-ALL cells in human patients in vivo.
|Pediatrics Hematology/Oncology/Bone Marrow Transplant Laboratories|
Research Complex One North
P18 Room 4403G
12800 East 19th Avenue
Aurora, CO 80045